fluorouracil has been researched along with Muscular Diseases in 4 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Muscular Diseases: Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we prospectively studied patients with metastatic breast cancer receiving capecitabine treatment in order to determine if sarcopenia was associated with a higher incidence of toxicity and a shorter time to tumor progression (TTP)." | 7.75 | Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. ( Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K, 2009) |
| " Here, we prospectively studied patients with metastatic breast cancer receiving capecitabine treatment in order to determine if sarcopenia was associated with a higher incidence of toxicity and a shorter time to tumor progression (TTP)." | 3.75 | Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. ( Baracos, VE; Koski, S; Mackey, JR; McCargar, LJ; Mourtzakis, M; Pituskin, E; Prado, CM; Reiman, T; Sawyer, MB; Tonkin, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Prado, CM | 1 |
| Baracos, VE | 1 |
| McCargar, LJ | 1 |
| Reiman, T | 1 |
| Mourtzakis, M | 1 |
| Tonkin, K | 1 |
| Mackey, JR | 1 |
| Koski, S | 1 |
| Pituskin, E | 1 |
| Sawyer, MB | 1 |
| Al-Sanna'a, NA | 1 |
| Van Kuilenburg, AB | 1 |
| Atrak, TM | 1 |
| Abdul-Jabbar, MA | 1 |
| Van Gennip, AH | 1 |
| Buecher, B | 1 |
| Blanc, JF | 1 |
| Magnien, F | 1 |
| Bechade, D | 1 |
| Lapprand, M | 1 |
| Oddes, B | 1 |
| Khan, U | 1 |
| Kakar, S | 1 |
| Akali, A | 1 |
| Bentley, G | 1 |
| McGrouther, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Patient Recorded Indexing Measurements[NCT05899205] | 300 participants (Anticipated) | Observational | 2021-06-01 | Recruiting | |||
| A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy[NCT01624051] | Phase 2 | 144 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 other studies available for fluorouracil and Muscular Diseases
| Article | Year |
|---|---|
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Body Composition; Body Mass Index; | 2009 |
Dihydropyrimidine dehydrogenase deficiency presenting at birth.
Topics: Age of Onset; Antimetabolites; Binding Sites; Digestive System Abnormalities; Dihydropyrimidine Dehy | 2005 |
[Severe myalgias: an unusual undesirable effect of levamisole combined with 5-fluorouracil].
Topics: Adenocarcinoma; Adjuvants, Immunologic; Antimetabolites, Antineoplastic; Colonic Neoplasms; Combined | 1996 |
Modulation of the formation of adhesions during the healing of injured tendons.
Topics: Animals; Cell Count; Disease Models, Animal; Fibroblasts; Fluorouracil; Hindlimb; Immunosuppressive | 2000 |